Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
Weber M, Kersting D, Riemann B, Brandenburg T, Führer-Sakel D, Grünwald F, Kreissl MC, Dralle H, Weber F, Schmid KW, Herrmann K, Jentzen W, Grafe H, Rischpler C, Theurer S, Bockisch A, Nagarajah J, Fendler WP.
Weber M, et al. Among authors: grafe h.
Clin Cancer Res. 2022 Oct 3;28(19):4194-4202. doi: 10.1158/1078-0432.CCR-22-0437.
Clin Cancer Res. 2022.
PMID: 35594174
Free PMC article.